Levogastrol

Levosulpiride, the active ingredient in Levogastrol, is a benzamide derivative (dopamine D2 receptor antagonist) presented as an oral dosage form for oral use. It is employed in the management of certain psychiatric conditions and functional gastrointestinal disorders in adult patients. GNH USA supplies Levogastrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosulpiride acts on dopaminergic pathways and gastrointestinal motility, making it useful for several psychiatric and gastro‑enterology indications. - Schizophrenia: reduces positive and negative symptoms by blocking central D2 receptors. - Depressive disorders: augments mood when used as an adjunctive therapy. - Functional dyspepsia: improves gastric emptying and relieves upper‑abdominal discomfort. - Gastroparesis: enhances gastric motility to alleviate delayed emptying. - Gastroesophageal reflux disease: reduces reflux episodes by promoting gastric clearance.

Levosulpiride may be associated with a range of adverse reactions.

Common Side Effects: - Drowsiness: mild sedation or fatigue. - Extrapyramidal symptoms: tremor, rigidity, or akathisia. - Gastrointestinal upset: nausea, abdominal cramps, or diarrhea. - Elevated prolactin: menstrual irregularities or galactorrhea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Severe extrapyramidal reactions: tardive dyskinesia or dystonia. - Cardiac arrhythmias: QT prolongation in susceptible individuals. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: excreted in milk; assess infant risk before use. - Renal impairment: dose adjustment may be required in severe dysfunction. - Elderly: increased sensitivity to extrapyramidal effects; start at low dose. - Concomitant CNS depressants: may enhance sedation. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Levosulpiride can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Antipsychotics with strong D2 antagonism: may exacerbate extrapyramidal symptoms. - QT‑prolonging agents (e.g., macrolides, fluoroquinolones): increase risk of cardiac arrhythmias. - CYP3A4 inhibitors (e.g., ketoconazole): raise plasma concentrations.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): enhanced sedation. - Anticholinergic drugs: may counteract pro‑kinetic effect. - Dopamine agonists (e.g., levodopa): reduced therapeutic efficacy.